EVALUATION OF THE EFFECTIVENESS OF THE COMPLEX OF ORGANIZATIONAL AND METHODOLOGICAL MEASURES IN THE PROCESS OF IMPLEMENTATION OF THROMBOLYTIC THERAPY FOR PATIENTS WITH ISCHEMIC STROKE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study was aimed to the evaluation of the effectiveness of the complex of organizational and methodological measures in the process of implementation of systemic thrombolytic therapy in 140 patients with ischemic stroke (IS) in the period from 2011 to 2015 under the settings of one healthcare organization. The results of the implementation of organizational and methodological measures led to increase in number of systemic thrombolysis procedures from 6 in 2011 (0.5% of all IS) to 71 in 2015 (6.6% of all IS), decrease (20.5 minutes ) in “door-to-needle" time during the analyzed period (from 68.5 minutes in 2011 to 48 minutes in 2015), and increase in the proportion of patients with satisfactory functional recovery of damaged neurological functions.

Full Text

Restricted Access

About the authors

M. A Kholopov

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

A. N Lazukin

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

N. N Rogova

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

K. N Rogov

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

K. N Kozlova

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

E. V Koshelkova

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

U. T.O Magomedov

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

A. N Baglikov

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

L. V Dmitrieva

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

V. K Andriyanova

SBHCIKR City Clinical Hospital № 2 "Sosnovaya Roscha"

Kaluga

A. P Tolmachev

SRI of Cerebrovascular Pathology and Stroke FSBEI HE RNSMU n.a. N.I. Pirogov of RMH

Moscow

N. A Shamalov

SRI of Cerebrovascular Pathology and Stroke FSBEI HE RNSMU n.a. N.I. Pirogov of RMH

Email: shamalovn@gmail.com
MD, Prof., SRI of Cerebrovascular Pathology and Stroke Moscow

References

  1. Krishnamurthi R.V., Feigin V.L., Forouzanfar M.H., Mensah G.A., Connor M., Bennett D.A., Moran A.E., Sacco R.L., Anderson L.M., Truelsen T., O'Donnell M., Venketasubramanian N., Barker-Collo S., Lawes C.M., Wang W, Shinohara Y, Witt E., Ezzati M., Naghavi M., Murray C.; Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010); GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob. Heath. 20131(5): e259-81.
  2. Клинические рекомендации по ведению больных с ишемическим инсультом и транзиторными ишемическими атаками (Национальные клинические рекомендации). www.femb.ru
  3. Клинические рекомендации по проведению тромболитической терапии при ишемическом инсульте (Национальные клинические рекомендации). www.femb.ru
  4. http://www.eso-stroke.org
  5. Jauch E.C., Saver J.L., Adams H.P Jr, Bruno A., Connors J.J., Demaerschalk B., Khatri P., McMullan PW. Jr, Qureshi A.I., Rosenfield K., Scott P.A., Summers D.R., Wang D.Z., Wintermark M., Yonas H.; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947.
  6. Fagan S.C., Morgenstern L.B., Petitta A., Ward R.E., Tilley B.C., Marler J.R., Levine S.R., Broderick J.P, Kwiatkowski T.G., Frankel M., Brott T.G., Walker M.D. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50:883-90.
  7. Guzauskas G.F, Boudreau D.M., Villa K.F, Levine S.R., Veenstra D.L. The cost-effectiveness of primary stroke centers for acute stroke care. Stroke. 2012;43:1617-23.
  8. Kruyt N.D., Nederkoorn P.J., Dennis M., leys D., Ringleb P.A., Rudd A.G., Vermeulen M., Stam J., Hacke W., Roos Y.B. Door-to-Needle Time and the Proportion of Patients Receiving Intravenous Thrombolysis in Acute Ischemic Stroke: Uniform Interpretation and Reporting. Stroke. 2013;44:3249-53.
  9. Тромболитическая терапия при ишемическом инсульте. Методические рекомендации / Под ред. В.И. Скворцовой. М., 2005.
  10. Brott T., Adams H.P. Jr., Olinger C.P., Marler J.R., Barsan W.G., Biller J., Spilker J., Holleran R., Eberle R., Hertzberg V., Rorick M., Moomaw C.J., Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:964-70.
  11. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scott. Med. J. 1957;2:200-15.
  12. Hacke W., Kaste M., Fieschi C., Toni D., Lesaffre E., von Kummer R., Boysen G., Bluhmki E., Hloxter G., Mahagne M.H., Hennerici M. Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13): 1017-25.
  13. Adams H.P Jr, Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., Marsh E.E. 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
  14. Hacke W., Kaste M., Bluhmki E., Brozman M., Davalos A., Guidetti D., Larrue V., Lees K.R., Medeghri Z., Machnig T., Schneider D., von Kummer R., Wahlgren N., Toni D. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N. Engl. J. Med. 2008;359:1317-29.
  15. Шамалов Н.А. Проблемы и перспективы реперфузионной терапии при ишемическом инсульте в России. Фарматека. 2015;9:14-9.
  16. Bray B.D., Campbell J., Cloud G.C., Hoffman A., Tyrrell P.J., Wolfe C.D., Rudd A.G. Bigger, Faster? Associations Between Hospital Thrombolysis Volume and Speed of Thrombolysis Administration in Acute Ischemic Stroke. Stroke. 2013;44:3129-35.
  17. Kunisawa S., Kobayashi D., Lee J., Otsubo T., Ikai H., Yokota C., Minematsu K., Imanaka Y. Factors associated with the administration of tissue plasminogen activator for acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 2014;23(4):724-31.
  18. Tissue Plasminogen Activator For Acute Ishemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 1995;333(24):1581-87.
  19. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V, Bluhmki E., Davis S., Donnan G., Schneider D., Diez-Tejedor E., Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245-51.
  20. Clark W.M., Wissman S., Albers G., Jhamandas J.H., Madden K.P., Hamilton S. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-26.
  21. Демин Т.В., Сайхунов М.В., Хасанова Д.Р Опыт применения внутривенного тромболизиса при ишемическом инсульте. Неврология, нейропсихиатрия, психосоматика. 2010;1:42-6.
  22. Скворцова В.И., Шамалов Н.А., Анисимов К.В., Рамазанов Г.Р. Результаты внедрения тромболитической терапии при ишемическом инсульте в Российской Федерации. Инсульт. Журн. неврологии и психиатрии им. С.С. Корсакова. 2010;12(2):17-22.
  23. Праздничкова Е.В., Алашеев А.М., Белкин А.А., Волкова Л.И. Возможность прогнозирования развития геморрагической трансформации при реперфузионной терапии ишемического инсульта в популяции пациентов Свердловской области. Неврология, нейропсихиатрия, психосоматика. 2015;(1):33-6.
  24. Wahlgren N., Ahmed N., Davalos A., Ford G.A., Grond M., Hacke W., Hennerici M.G., Kaste M., Kuelkens S., Larrue V., Lees K.R., Roine R.O., Soinne L., Toni D., Vanhooren G. investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-82.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media